Next Article in Journal
Chronic Eosinophilic Leukemia with FIP1L1-PDGFRA Transcripts after Occupational and Therapeutic Exposure to Radiation
Previous Article in Journal
A Report of Disseminated Adenocarcinoma Presenting as Thrombotic Thrombocytopenic Purpura
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Bosentan and Oral Anticoagulants in HIV Patients: What We Can Learn of Cases Reported So Far

by
José Antonio Morales-Molina
1,*,
Juan Enrique Martínez-de la Plata
1,
Olivia Urquízar-Rodríguez
1 and
María Angustias Molina-Arrebola
2
1
Pharmacy Department, Hospital de Poniente, 04700 El Ejido, Almería, Spain
2
Haematology Department, Hospital de Poniente, 04700 El Ejido, Almería, Spain
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2011, 3(2), e16; https://doi.org/10.4081/hr.2011.e16
Submission received: 5 July 2011 / Revised: 15 September 2011 / Accepted: 16 September 2011 / Published: 10 October 2011

Abstract

Pulmonary arterial hypertension is an infrequent but nevertheless serious life-threatening severe complication of HIV infection. It can be treated with bosentan and oral anticoagulants. Bosentan could induce the acenocoumarol metabolism and it increases the INR values. Until now, no study of interaction between bosentan and oral anticoagulants in HIV patients has reported. So we present a case of this interaction between these drugs and we reviewed MEDLINE to identify all the papers published so far. In our case, several weeks after increasing dose of bosentan acenocoumarol dose had to be progressively increased to 70 mg/week (+33%) without obtaining an adequate INR level (2.0–3.0). Forty-nine days later, we achieved a therapeutic INR with 90 mg/week of warfarin. The use of bosentan and oral anticoagulants together in these patients require a closer monitoring during first weeks of treatment, after increasing the bosentan dose and even during longer periods of time.
Keywords: acenocoumarol; bosentan; drug interactions; warfarin; HIV patients acenocoumarol; bosentan; drug interactions; warfarin; HIV patients

Share and Cite

MDPI and ACS Style

Morales-Molina, J.A.; Martínez-de la Plata, J.E.; Urquízar-Rodríguez, O.; Molina-Arrebola, M.A. Bosentan and Oral Anticoagulants in HIV Patients: What We Can Learn of Cases Reported So Far. Hematol. Rep. 2011, 3, e16. https://doi.org/10.4081/hr.2011.e16

AMA Style

Morales-Molina JA, Martínez-de la Plata JE, Urquízar-Rodríguez O, Molina-Arrebola MA. Bosentan and Oral Anticoagulants in HIV Patients: What We Can Learn of Cases Reported So Far. Hematology Reports. 2011; 3(2):e16. https://doi.org/10.4081/hr.2011.e16

Chicago/Turabian Style

Morales-Molina, José Antonio, Juan Enrique Martínez-de la Plata, Olivia Urquízar-Rodríguez, and María Angustias Molina-Arrebola. 2011. "Bosentan and Oral Anticoagulants in HIV Patients: What We Can Learn of Cases Reported So Far" Hematology Reports 3, no. 2: e16. https://doi.org/10.4081/hr.2011.e16

APA Style

Morales-Molina, J. A., Martínez-de la Plata, J. E., Urquízar-Rodríguez, O., & Molina-Arrebola, M. A. (2011). Bosentan and Oral Anticoagulants in HIV Patients: What We Can Learn of Cases Reported So Far. Hematology Reports, 3(2), e16. https://doi.org/10.4081/hr.2011.e16

Article Metrics

Back to TopTop